Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener TipRanks is the ...
Virtual Meeting to be held on February 19-20 hosted by BTIG. Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' ...
Hosted on MSN1mon
B. Riley Securities Initiates Coverage of Nektar Therapeutics (NKTR) with Buy RecommendationFintel reports that on January 8, 2025, B. Riley Securities initiated coverage of Nektar Therapeutics (NasdaqCM:NKTR) with a Buy recommendation. Analyst Price Forecast Suggests 302.86% Upside As ...
SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR) announced today that its drug candidate, rezpegaldesleukin, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ...
Nektar Therapeutics named Brian Kotzin its interim chief medical officer, succeeding Mary Tagliaferri, who stepped down from the role citing personal reasons. Kotzin will assist in the search for a ...
On Wednesday, B.Riley initiated coverage on shares of Nektar Therapeutics (NASDAQ:NKTR) with a Buy rating and a price target of $4.00. With the stock currently trading at $1.19, analyst targets ...
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seven brokerages that are currently covering the company, Marketbeat reports. Two ...
Therapeutics announced that the U.S. FDA has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback